350 related articles for article (PubMed ID: 29866017)
21. The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma.
Jiang E; Shangguan AJ; Chen S; Tang L; Zhao S; Yu Z
Cancer Lett; 2016 Sep; 379(2):262-7. PubMed ID: 26272181
[TBL] [Abstract][Full Text] [Related]
22. Promising Anti-Hepatitis C Virus Compounds from Natural Resources.
Wahyuni TS; Utsubo CA; Hotta H
Nat Prod Commun; 2016 Aug; 11(8):1193-1200. PubMed ID: 30725589
[TBL] [Abstract][Full Text] [Related]
23. Editorial: Phytochemicals and their Effects on Human Health.
Barros L; Ferreira ICFR
Curr Pharm Des; 2017; 23(19):2695-2696. PubMed ID: 28425864
[No Abstract] [Full Text] [Related]
24. Anti-hepatitis C virus activity and synergistic effect of Nymphaea alba extracts and bioactive constituents in liver infected cells.
Rehman S; Ashfaq UA; Ijaz B; Riazuddin S
Microb Pathog; 2018 Aug; 121():198-209. PubMed ID: 29775725
[TBL] [Abstract][Full Text] [Related]
25. Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Kawaoka T; Aikata H; Teraoka Y; Inagaki Y; Honda F; Hatooka M; Morio K; Morio R; Kobayashi T; Nagaoki Y; Nakahara T; Hiramatsu A; Tsuge M; Imamura M; Kawakami Y; Chayama K
Oncology; 2017; 92(6):335-346. PubMed ID: 28245484
[TBL] [Abstract][Full Text] [Related]
26. Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation.
Luk JM; Wang X; Liu P; Wong KF; Chan KL; Tong Y; Hui CK; Lau GK; Fan ST
Liver Int; 2007 Sep; 27(7):879-90. PubMed ID: 17696925
[TBL] [Abstract][Full Text] [Related]
27. Multitargeting and antimetastatic potentials of silibinin in human HepG-2 and PLC/PRF/5 hepatoma cells.
Ghasemi R; Ghaffari SH; Momeny M; Pirouzpanah S; Yousefi M; Malehmir M; Alimoghaddam K; Ghavamzadeh A
Nutr Cancer; 2013; 65(4):590-9. PubMed ID: 23659451
[TBL] [Abstract][Full Text] [Related]
28. Herbal Medicine for Glioblastoma: Current and Future Prospects.
Khan I; Mahfooz S; Hatiboglu MA
Med Chem; 2020; 16(8):1022-1043. PubMed ID: 32000653
[TBL] [Abstract][Full Text] [Related]
29. High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy.
Chen TM; Lin CC; Huang PT; Wen CF
Tumour Biol; 2016 Jun; 37(6):7129-37. PubMed ID: 26662957
[TBL] [Abstract][Full Text] [Related]
30. Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis.
Mann CD; Neal CP; Garcea G; Manson MM; Dennison AR; Berry DP
Eur J Cancer Prev; 2009 Feb; 18(1):13-25. PubMed ID: 19077560
[TBL] [Abstract][Full Text] [Related]
31. Primary prevention of hepatocellular carcinoma in developing countries.
Wild CP; Hall AJ
Mutat Res; 2000 Apr; 462(2-3):381-93. PubMed ID: 10767647
[TBL] [Abstract][Full Text] [Related]
32. Retinoid derivative Tp80 exhibits anti-hepatitis C virus activity through restoration of GI-GPx expression.
Nguyen BN; Okuno Y; Ajiro M; Iida K; Denawa M; Yamamoto M; Sakamoto N; Kagechika H; Hagiwara M
J Med Virol; 2017 Jul; 89(7):1224-1234. PubMed ID: 27922182
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis C Virus-Associated Cancers.
Yi Z; Yuan Z
Adv Exp Med Biol; 2017; 1018():129-146. PubMed ID: 29052135
[TBL] [Abstract][Full Text] [Related]
34. Herbal Medicine Offered as an Initiative Therapeutic Option for the Management of Hepatocellular Carcinoma.
Chen SR; Qiu HC; Hu Y; Wang Y; Wang YT
Phytother Res; 2016 Jun; 30(6):863-77. PubMed ID: 26879574
[TBL] [Abstract][Full Text] [Related]
35. JS-K, a nitric oxide prodrug, induces DNA damage and apoptosis in HBV-positive hepatocellular carcinoma HepG2.2.15 cell.
Liu Z; Li G; Gou Y; Xiao D; Luo G; Saavedra JE; Liu J; Wang H
Biomed Pharmacother; 2017 Aug; 92():989-997. PubMed ID: 28605880
[TBL] [Abstract][Full Text] [Related]
36. Environmental factors and risk for hepatocellular carcinoma.
Yu MC; Yuan JM
Gastroenterology; 2004 Nov; 127(5 Suppl 1):S72-8. PubMed ID: 15508106
[TBL] [Abstract][Full Text] [Related]
37. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
Michielsen P; Ho E; Francque S
Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
[TBL] [Abstract][Full Text] [Related]
38. Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein.
Zhang S; Gao S; Zhao M; Liu Y; Bu Y; Jiang Q; Zhao Q; Ye L; Zhang X
Cancer Lett; 2017 Apr; 392():94-104. PubMed ID: 28192212
[TBL] [Abstract][Full Text] [Related]
39. Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication.
Motoyama H; Tamori A; Kubo S; Uchida-Kobayashi S; Takemura S; Tanaka S; Ohfuji S; Teranishi Y; Kozuka R; Kawamura E; Hagihara A; Morikawa H; Enomoto M; Murakami Y; Kawada N
PLoS One; 2018; 13(3):e0194163. PubMed ID: 29534101
[TBL] [Abstract][Full Text] [Related]
40. Dioscin suppresses hepatocellular carcinoma tumor growth by inducing apoptosis and regulation of TP53, BAX, BCL2 and cleaved CASP3.
Zhang G; Zeng X; Zhang R; Liu J; Zhang W; Zhao Y; Zhang X; Wu Z; Tan Y; Wu Y; Du B
Phytomedicine; 2016 Nov; 23(12):1329-1336. PubMed ID: 27765352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
